Table 5.

Urinary symptoms at the metastatic hormone-sensitive prostate cancer stage and complications due to primary lesion progression at the metastatic castration-resistant prostate cancer stage in the study population.

	Group A	Group B	p value
Urinary symptoms at diagnosis	43 (79.6%)	44 (81.5%)	0.808
Relief of urinary symptoms at the mHSPC stage	34 (79.1%)	26 (59.1%)	0.044
Complications due to primary lesion progression at the mCRPC stage	8 (32.0%)	18 (42.9%)	0.378
Local symptomatic treatment	7 (13.0%)	17 (31.5%)	0.021

Group A cryoablation + ADT, group B ADT alone, ADT androgen deprivation therapy, mCRPC metastatic castration-resistant prostate cancer, mHSPC metastatic hormone-sensitive prostate cancer.